Journal of Oral Implantology Volume 47 Issue 5

The researchers stated that future studies should also focus on membrane thickness as well as examining residual concentrations of various grafting materials after epithelial closure.

LAWRENCE, Kan. (PRWEB)
November 02, 2021

Journal of Oral Implantology – After tooth extraction, alveolar ridge collapse can cause serious dental complications in patients for future implant surgeries. Preservation of the alveolar ridge helps to secure bone structure essential for the eventual successful dental implant placement. Traditionally, a type-1 bovine collagen membrane has been used to strengthen the ridge, but researchers are looking into alternative materials to assist in healing, function, and esthetics. “Jawbone preservation after tooth removal maintains the bone’s volume and quality for future implant placement,” researchers from the College of Dentistry, University of Kentucky, Lexington, and a private dental practice, Houston, Texas, state. They recently published the findings of their randomized controlled clinical study in the Journal of Oral Implantology that evaluates the use of human amnion-chorion membrane compared with a traditional type-1 bovine collagen membrane in an exposed socket preservation technique.

In their analysis, the researchers identified 43 patients that needed tooth extraction followed by a delayed implantation procedure. The patients were split into a 21-person experimental group receiving a human amnion-chorion membrane (experimental) and a 22-person control group receiving a bovine collagen membrane (control). The researchers wanted “to determine if intentional membrane exposure compromises ridge dimensions and bone quality.”

Researcher Ahmad Kutkut summarized the results by stating, “The volunteers underwent implant placement after an average healing period of 19.5 weeks. Core bone specimens were obtained for histomorphometric analyses. In addition, the clinical ridge dimensions were measured after extraction and at the time of delayed implant placement. As a result, no significant difference was observed between the experimental and control groups in the quality of the vital bone formation. In addition, the bone height and width did not differ, as determined by clinical measurements.”

The findings of this study suggest that using a human amnion-chorion membrane to aid in alveolar ridge preservation had no significant difference from using the traditional type 1 bovine collagen membrane. The researchers stated that future studies should also focus on membrane thickness as well as examining residual concentrations of various grafting materials after epithelial closure.

Dr. Kutkut reiterates these conclusions by saying, “Using a human amnion-chorion membrane as an open barrier did not compromise the healing or affect bone quality and quantity at the extraction sites.”

Full text of the article, “Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes in Alveolar Ridge Preservation: A Clinical and Histological Study” Journal of Oral Implantology, Vol. 47, No. 5, 2021, is available at https://doi.org/10.1563/aaid-joi-D-19-00335

###

About the Journal of Oral Implantology

The Journal of Oral Implantology is the official publication of the American Academy of Implant Dentistry and of the American Academy of Implant Prosthodontics. It is dedicated to providing valuable information to general dentists, oral surgeons, prosthodontists, periodontists, scientists, clinicians, laboratory owners and technicians, manufacturers, and educators. The JOI distinguishes itself as the first and oldest journal in the world devoted exclusively to implant dentistry. For more information about the journal or society, please visit http://www.joionline.org.

Share article on social media or email:

BoxLock Specimen Logistics Lab Box

BoxLock Control, the company’s cloud-based platform for managing data and devices, integrates into route management and lab information management systems to help reduce empty stops which account for roughly 30% of all specimen pickup attempts.

ATLANTA (PRWEB)
November 02, 2021

BoxLock, the supply chain access control platform, announced today at The Executive War College on Lab and Pathology Management, the rollout of an updated suite of specimen logistics solutions to meet the most demanding needs of laboratory customers.

Over 13 billion specimens were collected annually in the United States pre-pandemic. It’s estimated that over 70% of errors in the clinical testing process occur in the pre-analytical phase before the specimen ever reaches the laboratory for processing.

BoxLock’s new Cam Lock form factor includes Parsyl environmental sensor support, X-Ray capabilities and new hold time metrics so that laboratories can better service their clients with higher quality lab results, more reliable, efficient specimen logistics and enhanced visibility. BoxLock Control, the company’s cloud-based platform for managing data and devices, integrates into route management and lab information management systems to help reduce empty stops which account for roughly 30% of all specimen pickup attempts.

Currently in market with a number of regional and national laboratories, BoxLock’s specimen logistics solution reduces pre-analytical errors by giving labs and clinics insights into whether there are specimens available for pickup, how many specimens there are, the environmental conditions of the lab box and critical specimens along with the hold time. This historically elusive information is key to filling in the gap between specimen collection and specimen transportation.

For environmental monitoring, BoxLock has partnered with Parsyl, the supply chain data platform, makers of the Trek Tab and Trek Pro sensors. With the IoT devices from both companies and the underlying data, BoxLock and Parsyl are able to provide critical tools to monitor, prevent and protect specimen quality resulting from adverse conditions. This unique partnership creates an innovative and powerful way for laboratories to maintain the security and quality controls for their specimens throughout the preanalytical phase from clinic to laboratory.

Working with students and professors from Georgia Tech Supply Chain and Logistics Institute, BoxLock leverages customers’ existing data to help identify how to maximize the potential route savings. The net results in less drivers needed to service a larger customer base which is critical with labor shortage challenges.

BoxLock’s specimen logistics solutions are available from the company’s website at http://www.getboxlock.com/specimen-logistics and will additionally be available for purchase from McShane Welding, the nation’s proven leader in secure, courier, lab pickup box solutions. This partnership makes BoxLock’s platform as a service solution available as an add-on to the customized boxes that labs are currently purchasing through the same supplier most laboratories are procuring their lab boxes today.

BoxLock partners with in-house supply chain and logistics leaders in healthcare, aviation, operations and B2B e-Commerce sectors to provide customers with a unique suite of solutions that combine market leading IoT capabilities with advanced, practical tools for inventory management and access controls.

About BoxLock

BoxLock’s innovative supply chain access control platform helps businesses protect, track, and transfer assets. The company’s inventory, access, and security solutions make supply chains more efficient, accountable, and reliable wherever assets are stored or transferred. BoxLock’s smart devices and pioneering software platform seamlessly integrate into existing business systems, enabling companies unparalleled control over all facets of their supply chain, from pickup to delivery, and all points in between. The company’s transformative solutions are used by customers in healthcare, aviation, operations, logistics, and distribution. BoxLock is headquartered in Atlanta, GA. Find out more or book a consultation at http://www.getboxlock.com

About Parsyl

Parsyl is a fully integrated, data-driven insurer of essential supply chains. Parsyl’s combined IoT and software solution helps shippers of refrigerated cargo understand, mitigate and insure risks to goods as they move through the supply chain, both in transit and storage. Customers have the option of using Parsyl’s proprietary sensing devices or can integrate their own devices with the Parsyl platform. Parsyl is an approved Coverholder with Lloyd’s of London the premier market for hard to place risk. Parsyl is based in Denver and can be found at parsyl.com or on Twitter @ParsylHQ.

About McShane Welding

McShane is the leader in lockable box solutions for securing lab specimens, on-site documents, or other items until pick up by an authorized individual or courier. McShane Welding was founded and incorporated in December of 1973 by William McShane; business began operations in February of 1974. William, age 53, had worked in fabrication all his life and was previously employed at Erie Steel Products before striking out on his own. William’s business philosophy was to provide a quality product and the best service possible for his customers. Today, Jim McShane, William’s son, carries on that same belief in customer service.

Share article on social media or email:

We believe our advanced design stands apart from other spinal cord stimulation and peripheral nerve stimulation systems and provides meaningful advantages to clinicians, patients and the healthcare system.

CARLSBAD, Calif. (PRWEB)
November 02, 2021

Nalu Medical is pleased to announce its flagship micro-Implantable Pulse Generator (mIPG™) was selected as the 2021 winner of the MedTech Visionaries Award for Best MedTech Company and Best Medical Device in the field of neurology. The MedTech Visionaries Awards honor organizations that apply science and technology to real-world problems to advance MedTech solutions for businesses and consumers alike. Nalu Medical competed with innovative and creative entries from organizations and engineers from around the world.

The Nalu mIPG, was recognized by the judges for its creative and innovative application of technology to treat chronic intractable pain. Using advanced miniaturization and by eliminating the internal chemical battery in the implantable component, the Nalu mIPG is 27 times smaller than the largest commercially available implantable pulse generators (IPG).[1] Its innovative design no longer requires patients receiving implantable neurostimulation treatment to have an implanted battery. The small size of the mIPG translates into a less invasive procedure with the potential to reduce certain post-implant complications associated with larger incisions to accommodate traditional sized IPGs or battery replacement surgeries associated with IPGs containing implantable batteries.

Cleared for the spinal cord stimulation and peripheral nerve stimulation indications, the Nalu mIPG is uniquely powered wirelessly by an external Therapy Disc containing a battery and controlled by the patient via a smartphone-based app. Although micro-sized, the mIPG delivers stimulation outputs equal to larger IPGs but with additional capabilities around advanced waveforms, programming modes and upgradability.

“It’s an honor to be selected by the MedTech Visionaries as the medical device winner in the field of Neurology among many other innovative technologies,” said Earl Fender, President and CEO of Nalu Medical, Inc. “We believe our advanced design stands apart from other spinal cord stimulation and peripheral nerve stimulation systems and provides meaningful advantages to clinicians, patients and the healthcare system.”

About MedTech Visionaries Awards

Now in its 2nd year, the MedTech Visionaries Awards highlights the advancements and accomplishments of those in this industry who are disrupting the status quo. It is our mission to humanize the people behind this new frontier that takes ideas and makes them into reality.

About Nalu Medical

We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain. Our Nalu neurostimulation system, or Nalu system, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain. We designed our Nalu system to address major unmet needs in the treatment of chronic neuropathic pain and provide a differentiated value proposition for patients and physicians.

About the Nalu Neurostimulation System

Our proprietary Nalu system consists of a fully-featured, battery-free, miniaturized IPG (Implantable Pulse Generator), which is powered by an externally worn Therapy Disc and controlled through a smartphone-based remote control app. Our proprietary nPower microchip provides a broad menu of programmable therapy options. The Nalu Neurostimulation System is currently FDA-cleared for Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation indications. To learn more, visit http://nalumed.com.

Indications for Use

Spinal Cord Stimulation – The Nalu SCS system is indicated as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.

Peripheral Nerve Stimulation – The Nalu PNS system is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The Nalu Neurostimulation System for PNS is not intended to treat pain in the craniofacial region. The trial devices are solely used for trial stimulation (≤ 30 days) to determine efficacy before recommendation for a permanent (long term) device.

Nalu, the Nalu logo, mIPG and nPower are trademarks of Nalu Medical, Inc.

[1] Data on file, Nalu Medical, Inc. 2021.

Share article on social media or email:

“…This new acquisition consolidates our position as an undisputed and independent world leader in natural ingredients for Food and Nutrition,” states Mathieu Dondain, Nexira General Manager.

SOMERVILLE, N.J. (PRWEB)
November 02, 2021

The independent family-owned company Nexira (https://www.Nexira.com/), world leader in acacia fiber and natural plant-based ingredients for the food, nutrition and health industries, announced today its acquisition of the Swiss company UNIPEKTIN Ingredients AG, a specialist and leader in natural hydrocolloids and premium ingredients.

“This acquisition consolidates our position as a key player in natural plant-based ingredients – a dynamic market that caters to consumers seeking new sensory experiences and plant-based, natural, sustainably produced alternatives,” explains Olivier Houalla, Nexira Managing Director.

This acquisition is fully consistent with Nexira’s external growth and diversification strategy, strengthening its position in its core business – the production of natural plant-based ingredients for a variety of food product categories. With the addition of this new range of functional ingredients to its portfolio, Nexira consolidates its leadership in the fast-growing market segments of plant-based alternatives, dairy alternatives, and meat substitutes.

Swiss-based UNIPEKTIN Ingredients AG produces natural ingredients for the food industry. The company is an expert and world leader in the production of locust bean gum (LBG), used for its thickening, stabilizing properties. Its product range also includes a number of other specialty ingredients such as specific grades of tara gum, hydrolyzed guar gum, and beet fiber.

With a record turnover of more than $155M in 2021, and 90% of that total coming from exports, the Nexira Group is a leading producer of functional, organic, clean-label ingredients sourced responsibly and sustainably. Nexira guarantees a reliable supply chain and continued access to raw materials, with full traceability.

“After a successful diversification, providing a wide range of premium and branded botanical extracts to the health and nutrition markets, we are affirming our external growth strategy with the acquisition of a 100% equity interest in UNIPEKTIN Ingredients AG. This new acquisition consolidates our position as an undisputed and independent world leader in natural ingredients for Food and Nutrition,” states Mathieu Dondain, Nexira General Manager.

Nexira has a presence on 5 continents and in more than 80 countries with companies in the USA (celebrating 40 years in December), Mexico, Brazil, India, China, Japan, Singapore, France, and Africa. “This is an excellent opportunity to provide UNIPEKTIN Ingredients AG with enhanced international exposure, highly skilled customer service, and expanded recognition for reliable sourcing,” comments Robert Ackermann, member of the board of directors of UNIPEKTIN Ingredients AG.    

“Nexira will immediately implement its value innovation with a wider portfolio of solutions and new product developments launched at Food Ingredients Europe in late November,” concludes Mathieu Dondain.

The terms of the transaction have not been disclosed. Video asset announcing Nexira’s acquisition of UNIPEKTIN Ingredients AG.

About Nexira

Founded in 1895, Nexira is a global leader in natural ingredients and botanical extracts for the food, nutrition and dietary supplements industries.

With turnover of more than $155M, 90% of that from international sales, Nexira employs hundreds of people at its seven manufacturing plants worldwide and at its eight subsidiaries operating on five continents.

The French company built its reputation as the world leader in acacia (with a market share of more than 40%) and now manufactures a wide range of natural plant-based products with recognized health benefits.

Their portfolio of products includes highly functional and nutritional ingredients and a large number of active botanicals for health and nutrition applications such as weight management, stress management, sports nutrition, digestive health and cardiovascular health.

Nexira consistently leverages its technical and nutritional expertise on a daily basis, resulting in the development of innovative applications and new products for the food and beverage industry.

About UNIPEKTIN Ingredients AG

Founded in 1936, UNIPEKTIN Ingredients AG is a Swiss-based producer of premium, 100% natural ingredients for the food industry.

UNIPEKTIN Ingredients AG is an expert in food texturizing agents and is currently a well-recognized leader in locust bean gum, with unparalleled expertise in dairy applications and fruit processing. The company also produces tara gum, hydrolyzed guar gum, and beet fiber. UNIPEKTIN Ingredients AG assists its customers in developing new recipes, offering valuable know-how, and technical and application support.

Press Contact:

Melissa DeVincenzo

O.N. Marketing

melissa@onmarketingny.com

914.935.9541

Share article on social media or email: